A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Status

Recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-519563-18-00

Acronym

MK-5684-015

Enrollment

Registered

2025-08-21

Start date

2025-09-02

Completion date

Unknown

Last updated

2025-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer, Ovarian cancer, Endometrial cancer

Brief summary

Progression Free Survival (PFS) – All Cohorts

Detailed description

Overall Survival (OS) – All Cohorts, Clinical Benefit Rate (CBR) – Cohort A, Objective Response Rate (ORR) – All Cohorts, Duration of Response (DOR) – All Cohorts, Number of Participants who Experience One or More Adverse Events (AEs) – All Cohorts, Number of Participants who Discontinue Study Intervention Due to an AE – All Cohorts

Interventions

DRUGDEXAMETHASONE

DRUGTAMOXIFEN

DRUGEXEMESTANE

DRUGMEGESTROL

DRUGOpevesostat

DRUGMEDROXYPROGESTERONE

DRUGFULVESTRANT

DRUGLETROZOLE

DRUGFLUDROCORTISONE

DRUGHYDROCORTISONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Progression Free Survival (PFS) – All Cohorts	—

Secondary

Measure	Time frame
Overall Survival (OS) – All Cohorts, Clinical Benefit Rate (CBR) – Cohort A, Objective Response Rate (ORR) – All Cohorts, Duration of Response (DOR) – All Cohorts, Number of Participants who Experience One or More Adverse Events (AEs) – All Cohorts, Number of Participants who Discontinue Study Intervention Due to an AE – All Cohorts	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026